Unknown

Dataset Information

0

Metformin Prolongs Survival in Type 2 Diabetes Lung Cancer Patients With EGFR-TKIs.

ABSTRACT: Background: Metformin use reportedly reduces cancer risk and improves survival in lung cancer patients. This study aimed to investigate the effect of metformin use in patients with diabetes mellitus (DM) and lung cancer receiving epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. Methods: A nationwide, population-based cohort study was conducted using the Taiwan National Health Insurance Research Database. From January 1, 2004, to December 31, 2012, a total of 373 metformin and 1260 non-metformin lung cancer cohorts with type 2 DM and EGFR-TKI treatment were studied. Results: Metformin use was significantly associated with a reduced risk of death (hazard ratio: 0.73, 95% confidence interval [CI]: 0.62-0.85, P < .001), as well as a significantly longer median progression-free survival (9.2 months, 95% CI: 8.6-11.7, vs 6.4 months, 95% CI: 5.9-7.2 months, P < .001) and median overall survival (33.4 months, 95% CI: 29.4-40.2, vs 25.4 months, 95% CI: 23.7-27.2 months, P < 0.001). Conclusions: In conclusion, metformin may potentially enhance the therapeutic effect and increase survival in type 2 DM patients with lung cancer receiving EGFR-TKI therapy.

SUBMITTER: Hung MS 

PROVIDER: S-EPMC6696848 | biostudies-literature | 2019 Jan-Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Metformin Prolongs Survival in Type 2 Diabetes Lung Cancer Patients With EGFR-TKIs.

Hung Ming-Szu MS   Chuang Min-Chun MC   Chen Yi-Chuan YC   Lee Chuan-Pin CP   Yang Tsung-Ming TM   Chen Pau-Chung PC   Tsai Ying-Huang YH   Yang Yao-Hsu YH  

Integrative cancer therapies 20190101

<b>Background:</b> Metformin use reportedly reduces cancer risk and improves survival in lung cancer patients. This study aimed to investigate the effect of metformin use in patients with diabetes mellitus (DM) and lung cancer receiving epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. <b>Methods:</b> A nationwide, population-based cohort study was conducted using the Taiwan National Health Insurance Research Database. From January 1, 2004, to December 31, 2012, a to  ...[more]

Similar Datasets

Unknown Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway.
| S-EPMC7511631 | biostudies-literature
Unknown Metformin and lung cancer risk in patients with type 2 diabetes mellitus.
| S-EPMC5522244 | biostudies-other
Unknown Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.
| S-EPMC4979601 | biostudies-literature
Unknown Metformin therapy associated with survival benefit in lung cancer patients with diabetes.
| S-EPMC5085241 | biostudies-literature
Unknown miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type.
| S-EPMC4202169 | biostudies-literature
Unknown Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients.
| S-EPMC8071858 | biostudies-literature
Unknown Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer.
| S-EPMC3326682 | biostudies-other
Unknown Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.
| S-EPMC7058671 | biostudies-literature
Unknown Metformin use and lung cancer risk in patients with diabetes.
| S-EPMC4316372 | biostudies-literature
Unknown [A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer?with Uncommon EGFR Mutations].
| S-EPMC6754574 | biostudies-literature